Journal Mobile Options
Table of Contents
Vol. 51, No. 4, 2005
Issue release date: June 2005
Neuropsychobiology 2005;51:234–238
(DOI:10.1159/000085725)

Partial Normalization of Serum Brain-Derived Neurotrophic Factor in Remitted Patients after a Major Depressive Episode

Gervasoni N. · Aubry J.-M. · Bondolfi G. · Osiek C. · Schwald M. · Bertschy G. · Karege F.
Department of Psychiatry,aAdult Psychiatry and bNeuropsychiatry Services, Geneva University Hospital, Geneva, Switzerland

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

We had previously reported decreased serum brain-derived neurotrophic factor (BDNF) levels in depressed patients. In the present study, we tested the hypothesis that antidepressant treatment would normalize serum BDNF levels, at least in a subgroup of patients. Major depressed patients (15 females and 11 males) diagnosed according to DSM-IV criteria and healthy controls (13 females and 13 males) participated in this study. Serum BDNF was assayed with the ELISA method for depressed and remitted patients and the severity of depression was evaluated with the Montgomery-Asberg Depression Rating Scale. An analysis of variance showed that treatment had an effect [F(1, 24) = 4.46, p = 0.045] on the normalization of serum BDNF levels. We also found a correlation between the severity of depression (r = 0.51, p = 0.008), the pretreatment BDNF levels (r = 0.62, p = 0.001) and the difference in serum BDNF levels after antidepressant treatment. These results suggest that antidepressant treatment has a positive effect on serum BDNF levels and support the hypothesis of neurotrophic factor involvement in affective disorders.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Altar CA: Neurotrophins and depression. Trends Pharmacol Sci 1999;20:59–61.
  2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed. Washington, American Psychiatric Association, 1994.
  3. Apfel SC: Clinical Applications of Neurotrophic Factors. Philadelphia, Lippincott-Raven Press, 1997.
  4. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G: A comprehensive psychopathological rating scale. Acta Psychiatr Scand 1978;271:5–27.

    External Resources

  5. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999;286:1358–1362.
  6. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT: Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50:260–265.
  7. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M: Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res Mol Brain Res 1997;49:71–81.
  8. D’Sa C, Duman RS: Antidepressants and neuroplasticity. Bipolar Disord 2002;4:183–194.
  9. Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597–606.
  10. Durany N, Michel T, Kurt J, Cruz-Sanchez FF, Cervas-Navarro J, Riederer P: Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer’s disease brains. Int J Dev Neurosci 2000;18:807–813.
  11. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257–269.
  12. Ghosh A, Carnahan J, Greenberg ME: Requirement for BDNF in activity-dependent survival of cortical neurons. Science 1994;263:1618–1623.
  13. Honer WG, Falkai P, Bayer TA, Xie J, Hu L, Li HY, Arango V, Mann JJ, Dwork AJ, Trimble WS: Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex 2002;12:349–356.
  14. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM: Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002a;109:143–148.
  15. Karege F, Schwald M, Cisse M: Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002b;328:261–264.
  16. Kohara K, Kitamura A, Morishima M, Tsumoto T: Activity-dependent transfer of brain-derived neurotrophic factor to postsynaptic neurons. Science 2001;291:2419–2423.
  17. Lang UE, Hellweg R, Gallinat J: BDNF Serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 2004;29:795–798.
  18. Mamounas LA, Blue ME, Siuciak JA, Altar CA: Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 1995;15:7929–7939.
  19. Nibuya M, Morinobu S, Duman RS: Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995;15:7539–7547.
  20. Okazawa H, Murata M, Watanabe M, Kamei M, Kanazawa I: Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum. FEBS Lett 1992;313:138–142.
  21. Oliff HS, Berchtold NC, Isackson P, Cotman CW: Exercise-induced regulation of brain-derived neurotrophic factor (BDNF) transcripts in the rat hippocampus. Brain Res Mol Brain Res 1998;61:147–153.
  22. Pandey SC, Zhang D, Mittal N, Nayyar D: Potential role of the gene transcription factor cyclic AMP-responsive element binding protein in ethanol withdrawal-related anxiety. J Pharmacol Exp Ther 1999;288:866–878.
  23. Poo MM: Neurotrophins as synaptic modulators. Nature Reviews. Neuroscience 2001;2:24–32.
  24. Russo-Neustadt A, Beard RC, Cotman CW: Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999;21:679–682.
  25. Russo-Neustadt A, Ha T, Ramirez R, Kesslak JP: Physical activity-antidepressant treatment combination: Impact on brain-derived neurotrophic factor and behavior in an animal model. Behav Brain Res 2001;120:87–95.
  26. Shelton RC: Cellular mechanisms in the vulnerability to depression and response to antidepressants. Psychiatr Clin North Am 2000;23:713–729.
  27. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70–75.
  28. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS: Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002;22:3251–3261.
  29. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM: Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997;56:131–137.
  30. Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim YM, Tsan G, Schaffner S, Kirov G, Jones I, Owen M, Craddock N, DePaulo JR, Lander ES: Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry 2002;7:579–593.
  31. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, Koizumi S, Wakabayashi K, Takahashi H, Someya T, Nawa H: Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000;5:293–300.
  32. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M: Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J Psychiatr Res 2001;35:83–94.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50